EA202190654A1 - Гетероциклическое соединение - Google Patents
Гетероциклическое соединениеInfo
- Publication number
- EA202190654A1 EA202190654A1 EA202190654A EA202190654A EA202190654A1 EA 202190654 A1 EA202190654 A1 EA 202190654A1 EA 202190654 A EA202190654 A EA 202190654A EA 202190654 A EA202190654 A EA 202190654A EA 202190654 A1 EA202190654 A1 EA 202190654A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ring
- compound
- heterocyclic
- connection
- heterocyclic connection
- Prior art date
Links
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018167488 | 2018-09-07 | ||
| PCT/JP2019/035233 WO2020050409A1 (en) | 2018-09-07 | 2019-09-06 | Heterocyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190654A1 true EA202190654A1 (ru) | 2021-05-27 |
Family
ID=68063002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190654A EA202190654A1 (ru) | 2018-09-07 | 2019-09-06 | Гетероциклическое соединение |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11932657B2 (enExample) |
| EP (1) | EP3847176A1 (enExample) |
| JP (1) | JP7448527B2 (enExample) |
| KR (1) | KR102810086B1 (enExample) |
| CN (1) | CN112654627A (enExample) |
| AU (2) | AU2019335968B2 (enExample) |
| CA (1) | CA3109610A1 (enExample) |
| EA (1) | EA202190654A1 (enExample) |
| IL (1) | IL280821B2 (enExample) |
| SG (1) | SG11202101963XA (enExample) |
| TW (1) | TWI854995B (enExample) |
| WO (1) | WO2020050409A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7448527B2 (ja) | 2018-09-07 | 2024-03-12 | 大塚製薬株式会社 | ヘテロ環式化合物 |
| CA3155466A1 (en) | 2019-12-09 | 2021-06-17 | Otsuka Pharmaceutical Co., Ltd. | Acrylamide compounds |
| JP2023515128A (ja) | 2020-02-26 | 2023-04-12 | ジャガー セラピューティクス ピーティーイーリミテッド | Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体 |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN115215720B (zh) * | 2021-04-19 | 2023-08-22 | 中国科学院化学研究所 | 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用 |
| WO2022228399A1 (zh) * | 2021-04-27 | 2022-11-03 | 山东轩竹医药科技有限公司 | 三并环类usp1抑制剂及其用途 |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN118076613A (zh) * | 2021-09-02 | 2024-05-24 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的化合物 |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN119948035A (zh) | 2022-10-03 | 2025-05-06 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的化合物 |
| WO2024090138A1 (ja) * | 2022-10-29 | 2024-05-02 | 松本油脂製薬株式会社 | 弾性繊維用処理剤及びその利用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| EA026134B1 (ru) | 2010-12-16 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Трициклические ингибиторы pi3k и способы их применения |
| WO2014138485A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| WO2016204256A1 (ja) | 2015-06-16 | 2016-12-22 | 国立大学法人京都大学 | 高機能性血小板の製造方法 |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| WO2019167973A1 (en) | 2018-03-01 | 2019-09-06 | Kyoto University | Cell cycle progression inhibitor |
| JP7448527B2 (ja) | 2018-09-07 | 2024-03-12 | 大塚製薬株式会社 | ヘテロ環式化合物 |
| CA3155466A1 (en) | 2019-12-09 | 2021-06-17 | Otsuka Pharmaceutical Co., Ltd. | Acrylamide compounds |
| JP2022188761A (ja) | 2021-06-09 | 2022-12-21 | 大塚製薬株式会社 | 窒素原子含有複素環化合物を用いる血小板産生方法 |
-
2019
- 2019-09-06 JP JP2021512830A patent/JP7448527B2/ja active Active
- 2019-09-06 CN CN201980058108.7A patent/CN112654627A/zh active Pending
- 2019-09-06 IL IL280821A patent/IL280821B2/en unknown
- 2019-09-06 EA EA202190654A patent/EA202190654A1/ru unknown
- 2019-09-06 EP EP19773956.8A patent/EP3847176A1/en active Pending
- 2019-09-06 SG SG11202101963XA patent/SG11202101963XA/en unknown
- 2019-09-06 US US17/271,479 patent/US11932657B2/en active Active
- 2019-09-06 WO PCT/JP2019/035233 patent/WO2020050409A1/en not_active Ceased
- 2019-09-06 KR KR1020217009658A patent/KR102810086B1/ko active Active
- 2019-09-06 CA CA3109610A patent/CA3109610A1/en active Pending
- 2019-09-06 AU AU2019335968A patent/AU2019335968B2/en active Active
- 2019-09-06 TW TW108132216A patent/TWI854995B/zh active
-
2024
- 2024-01-18 US US18/416,261 patent/US20240208999A1/en active Pending
- 2024-06-04 AU AU2024203760A patent/AU2024203760A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210056373A (ko) | 2021-05-18 |
| KR102810086B1 (ko) | 2025-05-21 |
| TWI854995B (zh) | 2024-09-11 |
| WO2020050409A1 (en) | 2020-03-12 |
| AU2024203760A1 (en) | 2024-06-20 |
| CN112654627A (zh) | 2021-04-13 |
| AU2019335968A1 (en) | 2021-05-06 |
| CA3109610A1 (en) | 2020-03-12 |
| TW202035423A (zh) | 2020-10-01 |
| JP2021536482A (ja) | 2021-12-27 |
| SG11202101963XA (en) | 2021-03-30 |
| IL280821A (en) | 2021-04-29 |
| NZ774547A (en) | 2025-10-31 |
| US20240208999A1 (en) | 2024-06-27 |
| JP7448527B2 (ja) | 2024-03-12 |
| EP3847176A1 (en) | 2021-07-14 |
| IL280821B1 (en) | 2024-10-01 |
| US20210340157A1 (en) | 2021-11-04 |
| US11932657B2 (en) | 2024-03-19 |
| IL280821B2 (en) | 2025-02-01 |
| AU2019335968B2 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180011A1 (ar) | مشتقات بيرولو [1، 2-b]بيريدازين | |
| CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
| CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
| MX2013010334A (es) | Derivados de diespiropirrolidina. | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| EA201691085A1 (ru) | Замещенные бензамиды и способы их применения | |
| EA201400247A1 (ru) | Сельскохозяйственная и садоводческая фунгицидная композиция | |
| EA201101673A1 (ru) | Замещенные хиназолины в качестве фунгицидов | |
| ECSP12007067A (es) | Derivados de quinazolinona útiles como antagonistas vanilloides | |
| EA201070994A1 (ru) | Конденсированное гетероциклическое производное и его применение | |
| PH12016502358B1 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
| BR112012017277A2 (pt) | Compostos e métodos | |
| PH12018500582A1 (en) | Crosslinked nucleic acid guna, method for producing same, and intermediate compound | |
| EA201070876A1 (ru) | Трициклические соединения, обладающие антагонистической активностью по отношению к кортикотропин-высвобождающему фактору, и содержащие их фармацевтические композиции | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| MX388826B (es) | Compuesto peptidico. | |
| EA201600248A1 (ru) | Антибактериальные производные 2h-индазола | |
| TR201900393T4 (tr) | 1,2-Dihidro-3H-Pirolo[1,2-C]İmidazol-3-On Türevleri Ve Bunların Antibakteriyel Ajanlar Olarak Kullanımı | |
| MY161134A (en) | Piperazine compound having a pgds inhibitory effect | |
| SG11201809243YA (en) | Condensed heterocyclic compound | |
| EA201590069A1 (ru) | Пиримидиноновые производные в качестве антималярийных средств | |
| MY160882A (en) | Biocidal composition and method | |
| EA202190880A1 (ru) | Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение | |
| PH12018500301A1 (en) | Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterials |